Purple Biotech (PPBT) announced a collaboration with Converge Bio to accelerate and enhance Purple Biotech’s next-generation tri-specific antibody platform leveraging advanced generative AI capabilities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PPBT:
- Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)
- Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns
- Purple Biotech Updates March 2026 Corporate Outlook and Pipeline Milestones
- Purple Biotech regains compliance with Nasdaq
- Purple Biotech Regains Nasdaq Compliance on Minimum Bid Price